Healthcare

Valion Bio Sets 30-Day Agenda Around Entolimod, Velocity Bioworks and Strategic Review

Valion Bio’s interim CEO has outlined a 30-day agenda focused on advancing the company’s biologics pipeline, developing commercial opportunities for Velocity Bioworks and assessing potential strategic arrangements for the CDMO.

Published:
Reading Time
3 min

Valion Bio, Inc. (NASDAQ:VBIO) has outlined the initial priorities identified by Interim Chief Executive Officer Dean Zikria after his first 30 days in the role. The agenda centres on advancing Entolimod and other pipeline programmes, developing customer and revenue opportunities for wholly owned subsidiary Velocity Bioworks, and reviewing possible strategic arrangements involving the contract development and manufacturing organisation.

#Three areas of focus

Valion said its review is organised around three areas: progressing Entolimod and other assets; pursuing customers and revenue capabilities for Velocity; and assessing partnerships, co-investment structures, licensing arrangements and other potential transactions involving the CDMO.

Mr. Zikria, who has served on Valion’s Board of Directors for more than seven years, said the review would focus on development progress, commercial activity and capital allocation. The company has not committed to a specific transaction involving Velocity.

#Entolimod development programmes

Entolimod is Valion’s lead biologic candidate for Acute Radiation Syndrome, or ARS. The programme is designed to activate innate immune pathways and is being studied for its potential to protect cells and tissues from severe radiation-related injury in prophylactic and therapeutic settings.

Valion said the programme has received approximately $35.6 million in non-dilutive funding from U.S. government agencies. Entolimod also has U.S. Food and Drug Administration Fast Track and Orphan Drug designations for ARS, alongside human safety data that the company described as a foundation for further development.

One current programme is being conducted by the Armed Forces Radiobiology Research Institute under a U.S. Department of War-funded effort focused on radiation-induced gastrointestinal injury. Valion said FDA-approved medical countermeasures for ARS currently address the haematopoietic, or bone-marrow, component of radiation injury, while no treatment is currently approved for the gastrointestinal component.

The company is also working with Sheba Medical Center towards a clinical trial involving cancer patients receiving high doses of irradiation. Separately, Valion and Shear Kershman Laboratories are pursuing an oral mucosal version of Entolimod using SKL’s BioViscid™ drug-delivery platform. Any such formulation would remain dependent on successful development and validation, with potential use affected by pharmacokinetics, stability, dosing, regulatory status and procurement requirements.

#Entolasta and the wider pipeline

Valion said it plans to advance Entolasta, a next-generation Toll-like receptor 5 agonist being developed for potential therapeutic applications including oncology supportive care.

The company said decisions on advancing its programmes and pursuing possible partnering opportunities will take account of available evidence, milestones and resource requirements. Valion’s broader pipeline includes potential programmes in neutropenia and immune dysfunction.

#Velocity Bioworks commercial strategy

Velocity Bioworks is Valion’s wholly owned contract development and manufacturing organisation. It provides development and manufacturing services for Valion’s internal pipeline and offers traditional CDMO services to biotechnology companies seeking U.S.-based manufacturing for early-phase biologics programmes.

Valion is pursuing new customer relationships for Velocity and seeking to convert discussions into customer programmes. The company said these efforts represent a potential near-term opportunity to improve facility utilisation, generate service revenue and establish relationships that may support longer-term business growth.

#Strategic options remain under review

Valion said the strategic review of Velocity may include partnerships, joint ventures, co-investment arrangements, licensing deals and/or a sale. The company said it is assessing which structure could help the CDMO expand its commercial reach and access resources while supporting Valion’s strategic and financial priorities.

There is no assurance that the review will produce an agreement or transaction on favourable terms, or at all. Valion does not expect to disclose developments unless the evaluation has been completed or its Board of Directors determines that disclosure is appropriate or legally required. The announcement did not provide a completion date for the review.

#About Valion Bio

Valion Bio is a clinical-stage biopharmaceutical company developing biologics that activate innate immune pathways for cytoprotection and immune modulation in conditions involving radiation, disease and immune dysregulation. Its common stock trades on the Nasdaq Capital Market under the symbol NASDAQ:VBIO.

#Key Takeaways

  • Interim CEO Dean Zikria has set a 30-day agenda focused on Entolimod, other pipeline assets and Velocity Bioworks.
  • Valion said Entolimod has received approximately $35.6 million in non-dilutive funding from U.S. government agencies.
  • Entolimod is being evaluated in gastrointestinal radiation injury, a potential cancer-related clinical trial and an oral mucosal formulation programme.
  • Valion plans to advance Entolasta, a next-generation Toll-like receptor 5 agonist for potential therapeutic applications including oncology supportive care.
  • The company is reviewing potential strategic arrangements for Velocity but has not committed to a transaction and has provided no completion date.

Original source: Read original article

Frequently Asked Questions